Pharma-Bio Serv (OTCMKTS:PBSV) Releases Earnings Results, Beats Estimates By $0.35 EPS

Pharma-Bio Serv (OTCMKTS:PBSVGet Free Report) issued its earnings results on Monday. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.35, reports. Pharma-Bio Serv had a negative net margin of 8.18% and a negative return on equity of 5.61%. The firm had revenue of $2.47 million during the quarter, compared to analyst estimates of $2.70 million.

Pharma-Bio Serv Stock Down 21.8 %

PBSV stock opened at $0.43 on Wednesday. Pharma-Bio Serv has a 52 week low of $0.31 and a 52 week high of $0.90. The company has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.57. The firm has a market capitalization of $9.86 million, a P/E ratio of -14.33 and a beta of 0.53.

Pharma-Bio Serv Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, March 20th. Shareholders of record on Friday, February 28th will be given a dividend of $0.075 per share. The ex-dividend date of this dividend is Friday, February 28th. Pharma-Bio Serv’s dividend payout ratio (DPR) is currently -250.00%.

Pharma-Bio Serv Company Profile

(Get Free Report)

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies.

Read More

Earnings History for Pharma-Bio Serv (OTCMKTS:PBSV)

Receive News & Ratings for Pharma-Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma-Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.